ELECTROCORE INC
ECORNASDAQTrading Snapshot
- Day Range
- $4.06 β $4.81
- 52-Week Range
- $4.37 β $12.70
- Volume (shares)
- 6,187
- Avg Volume (shares)
- β
- Shares Outstanding
- 9.0M
- Next Earnings
- 2027-03-18
Fundamentals Snapshot
- Annual Revenue
- $32M
- Last Q Revenue
- $10M
- P/E Ratio
- β
- P/S Ratio
- 1.1x
- EPS (TTM)
- $-1.66
- Dividend Yield
- β
- Dilution (1yr)
- +7.0%
ELECTROCORE INC
ECORAbout ELECTROCORE INC
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates

Randomized Study of Non-Invasive Autonomic Neuromodulation for Long COVID Published Online in Neuromodulation
Randomized, open-label, hypothesis-generating study (541 participants enrolled; 250 met final analysis criteria) evaluated two proprietary non-invasive neuromodulation technologies, electroCore's cervical vagus nerve sti

electroCore (ECOR) Upgraded to Buy: Here's What You Should Know
electroCore (ECOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
ROCKAWAY, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuit

electroCore, Inc. (ECOR) Q3 2026 Earnings Call Transcript
electroCore, Inc. (ECOR) Q3 2026 Earnings Call Transcript

electroCore, Inc. (ECOR) Reports Q3 Loss, Misses Revenue Estimates
electroCore, Inc. (ECOR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.4 per share a year ago.

electroCore Q3 Earnings Call Highlights
electroCore NASDAQ: ECOR reported record third-quarter sales and a narrower loss, but revised its 2026 revenue outlook as changes to its sales organization took longer than expected to reach the full field.